Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.39 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14570493 | 0.85 | IDO1 (0.43) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL265486 | 0.84 | IDO1 (0.52) | RXRARXRBRXRGPRKCAPRKCD | |
| SCHEMBL10316301 | 0.84 | NOS1 (0.42) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL16380850 | 0.84 | PGK1 (0.36) | RXRARXRBRXRGGRIN2BIDH1 | |
| SCHEMBL16767879 | 0.83 | GRIN2B (0.44) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL806121 | 0.81 | IDO1 (0.41) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL19051205 | 0.81 | TACR1 (0.43) | RXRARXRBPGK1PGK2 | |
| SCHEMBL799008 | 0.81 | IDO1 (0.41) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL799078 | 0.79 | IDO1 (0.39) | GRIN2BIDH1IDO1MRGPRX4RAPGEF4 | |
| SCHEMBL16951240 | 0.79 | RXRA (0.45) | RXRARXRBRXRGPRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2020-05-21 | — | — | US | disclosed |
| EP-2935249-B1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-12-12 | — | — | EP | disclosed |
| CN-104968656-B | autotaxin inhibitors | 诺华股份有限公司 | 2017-08-11 | — | — | CN | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-20170007614-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-01-12 | — | — | US | disclosed |
| US-9409895-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| US-9181245-B2 | Substituted pyrido[1,2-a]pyrazines and substituted pyrido[1,2-a][1,4]diazepines for the treatment of (inter alia) Alzheimer's disease | Janssen Pharmaceuticals, Inc. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| EP-2935249-A2 | AUTOTAXIN INHIBITORS | Novartis AG (CH) | 2015-10-28 | — | — | EP | disclosed |
| CN-104968656-A | AUTOTAXIN INHIBITORS | NOVARTIS AG | 2015-10-07 | — | — | CN | disclosed |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | CELLZOME LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| WO-2014097151-A2 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2014-06-26 | — | — | WO | disclosed |
| US-20140171404-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-20140171403-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8318656-B2 | Production processes and systems, compositions, surfactants, monomer units, metal complexes, phosphate esters, glycols, aqueous film forming foams, and foam stabilizers | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | E.I. DU PONT DE NEMOURS AND COMPANY CHEMTURA CORPORATION (US) | 2012-03-22 | — | — | US | disclosed |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | SMITHKLINE BEECHAM CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-4950673-A | 5-amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1990-08-21 | — | — | US | disclosed |
| US-4816469-A | 5-Amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4721791-A | 5-amino or substituted amino 1,2,3-triazoles | MERCK & CO., INC. (US) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | RXRA 3604/4885RXRB 3047/4885RXRG 3100/4885 |
| US-20140171403-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | RXRA 3196/4885RXRB 2917/4885RXRG 2689/4885 |
| US-20150141411-A1 | SUBSTITUTED 3,4-DIHYDRO-2H-PYRIDO[1,2-A]PYRAZINE-1,6-DIONE DERIVATIVES USEFUL FOR THE TREATMENT OF (INTER ALIA) ALZHEIMER'S DISEASE | BACE1, PSEN1, BACE2 | RXRA 1144/4885RXRB 1526/4885RXRG 1905/4885 |
| US-20120071689-A1 | PRODUCTION PROCESSES AND SYSTEMS, COMPOSITIONS, SURFACTANTS, MONOMER UNITS, METAL COMPLEXES, PHOSPHATE ESTERS, GLYCOLS, AQUEOUS FILM FORMING FOAMS, AND FOAM STABILIZERS | FOS, AFF4, AFF1 | RXRA 823/4885RXRB 1326/4885RXRG 831/4885 |
| US-20200157088-A1 | BENZENE FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | NR2C2, NR0B2, NR0B1 | RXRA 131/4885RXRB 20/4885RXRG 155/4885 |
| US-20140171404-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | RXRA 3578/4885RXRB 3178/4885RXRG 3139/4885 |
| US-20100240642-A1 | 1H-Indole-2-Carboxylic Acid Derivatives Useful As PPAR Modulators | PPARD, PPARA, PPARG | RXRA 36/4885RXRB 44/4885RXRG 38/4885 |
| US-20170007614-A1 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | RXRA 3196/4885RXRB 2917/4885RXRG 2689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.